Pharmaco-metabonomic phenotyping and personalized drug treatment
T. Andrew Clayton(Imperial College London), Jeremy K. Nicholson(Imperial College London), David Baker(Queen Mary University of London), Jeremy R. Everett(Pfizer (United Kingdom)), John C. Lindon(Imperial College London), Jean-Loïc Le Net(Pfizer (France)), G. Hanton(Pfizer (France)), Claude Charuel(Pfizer (France)), Rosalind Walley(Pfizer (United Kingdom)), Olivier Cloarec, Jean-Pierre Provost(Pfizer (France)), Henrik Antti(Umeå University)
Cited by 827
Related Papers
Proposed minimum reporting standards for chemical analysis
|Metabolomics|2007|5k
'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data
|Xenobiotica|1999|3.9k
Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts
|Nature Protocols|2007|2.1k
Metabonomics: a platform for studying drug toxicity and gene function
|Nature Reviews Drug Discovery|2002|1.9k
Metabonomics
|Nature|2008|1.9k